The halt will remain in place until the opening of trade on Monday 24th April 2017, or earlier if an announcement is made to the market.
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
“We are delighted to report positive results from the Phase II study. We believe PeproStat is a first-in-class product which could enter the large and growing haemostat market as early as 2020.”